Cryoprecipitated Antihemophilic Factor from Human Plasma from Japan
Cryoprecipitate is a human plasma fraction rich in factor VIII, fibrinogen, and von Willebrand factor, prepared by thawing frozen plasma at 1-6°C. It treats hemophilia A and fibrinogen deficiencies. Falls under HTS 3002.12.00.10 as a human blood fraction derived from plasma.
Duty Rate — Japan → United States
15%
Rate breakdown
9903.04.6215%Pharmaceuticals: patented pharma from JP/EU/KR/CH/LI — 15% floor rate
9903.05.860%Universal product exemption (U.S. note 52(b))
9903.05.900%Articles already subject to Section 232 (steel/aluminum/copper + derivatives, autos + parts, wood, medium/heavy vehicles + parts, semiconductors, patented pharma) — U.S. note 52(f)
Import Tips
• Provide CBER registration and lot-specific release certificates from FDA-licensed fractionators
• Declare exact protein content and potency per unit to avoid misclassification during entry
• Watch for expiration dating issues; expired plasma risks waste pharmaceutical classification under 3006